2-(2,6-dimethylpyridin-4-yl)acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2,6-dimethylpyridin-4-yl)acetic acid
• 英文别名: (2,6-Dimethyl-4-pyridinyl)acetic acid
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: UDZSKYLTWZYMSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,6-dimethylpyridin-4-yl)acetic acid 在 dimethyl sulfide borane 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 1-(2-Aza-bicyclo[2.2.2]oct-2-yl)-2-(2-(3,5-dimethyl-phenyl)-3-{(S)-2-[2-(2,6-dimethyl-pyridin-4-yl)-ethylamino]-1-methyl-ethyl}-1H-indol-5-yl)-2-methyl-propan-1-one
  参考文献：
  名称：

  Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists

  摘要：

  The synthesis of a number of indole GnRH antagonists is described. Oxidation of the pyridine ring nitrogen, combined with alkylation at the two position, led to a compound with an excellent in vitro activity profile as well as oral bioavailability in both rats and dogs. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00751-5
• 作为产物：
  描述：

  methyl 2-(2,6-dimethylpyridin-4-yl)acetate 在 lithium hydroxide monohydrate 作用下， 以 甲醇 、 水 为溶剂， 以98 %的产率得到2-(2,6-dimethylpyridin-4-yl)acetic acid
  参考文献：
  名称：

  [EN] COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF
  [FR] COMPOSÉS ASSURANT LA MÉDIATION DE LA DÉGRADATION DE PROTÉINES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Described herein, in part, are compounds that bind to and modulate the surface of cereblon and mediate the degradation of GSPT1, and are therefore useful in the treatment of various disorders, such as cancer.

  公开号：

  WO2023069731A1

文献信息

• 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US20140371204A1

  公开（公告）日：2014-12-18

  The invention relates to compounds of Formula (I) wherein ring A, X, (R 1 ) n , R 2 , R 3 , R 4 , R 4′ , R 5 , n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)化合物，其中环A、X、(R1)n、R2、R3、R4、R4′、R5、n和p如描述中所述；涉及药用可接受的盐，以及将此类化合物用作药物，尤其是用作CXCR3受体的调节剂。
• [EN] 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES<br/>[FR] COMPOSÉS DE 4-(BENZOIMIDAZOL-2-YLE)-THIAZOLE ET DÉRIVÉS AZA ASSOCIÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013114332A1

  公开（公告）日：2013-08-08

  The invention relates to compounds of Formula (I) wherein ring A, X, (R1)n, R2, R3, R4, R4', R5, n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)化合物，其中环A、X、(R1)n、R2、R3、R4、R4'、R5、n和p如描述中所述；涉及药用可接受的盐，以及将此类化合物用作药物，尤其是用作CXCR3受体的调节剂。
• 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US09266876B2

  公开（公告）日：2016-02-23

  The invention relates to compounds of Formula (I), wherein ring A, X, (R1)n, R2, R3, R4, R4′, R5, n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)的化合物，其中环A、X、(R1)n、R2、R3、R4、R4′、R5、n和p如说明书所述；其药学上可接受的盐；以及将这些化合物用作药物，特别是作为CXCR3受体调节剂。
• 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2809668B1

  公开（公告）日：2017-04-12
• US9266876B2
  申请人：——

  公开号：US9266876B2

  公开（公告）日：2016-02-23